To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EGFR), and CD3 on T-cells, thereby directing immune cells to eliminate EGFRvIII-positive tumor cells. Using phage display, we identified scFv antibodies selectively binding to EGFRvIII. These highly EGFRvIII-specific, fully human scFv were substantially improved by affinity maturation, achieving KDs in the picomolar range, and were used to construct a set of bispecific EGFRvIII-targeting TandAbs with a broad range of binding and cytotoxic properties. These antibodies exhibited an exquisite specificity for a distinguished epitope in the N-terminal portion of EGFRvIII, as shown on recombinant antigen in Western Blot, SPR, and ELISA, as well as on antigen-expressing cells in FACS assays, and did not bind to the wild-type EGFR. High-affinity EGFRvIII/CD3 TandAbs were most potent in killing assays, displaying cytotoxicity toward EGFRvIII-expressing CHO, F98 glioma, or human DK-MG cells with EC50 values in the range of 1-10 pM in vitro. They also demonstrated dose-dependent growth control in vivo in an EGFRvIII-positive subcutaneous xenograft tumor model. Together with the tumor-exclusive expression of EGFRvIII, the EGFRvIII/CD3 TandAbs' high specificity and strictly target-dependent activation with no off-target activity provide an opportunity to target tumor cells and spare normal tissues, thereby reducing the side effects associated with other anti-EGFR therapies. In summary, EGFRvIII/CD3 TandAbs are highly attractive therapeutic antibody candidates for selective immunotherapy of EGFRvIII-positive tumors.

AbCheck s r o Plzen Czechia

Affimed GmbH Heidelberg Germany

Zobrazit více v PubMed

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 19:3159–67.10.1093/emboj/19.13.3159 PubMed DOI PMC

Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol (2004) 44:195–217.10.1146/annurev.pharmtox.44.101802.121440 PubMed DOI

Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:203–12.10.1016/0092-8674(90)90801-K PubMed DOI

Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 313:144–7.10.1038/313144a0 PubMed DOI

Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res (2003) 284:122–30.10.1016/S0014-4827(02)00104-0 PubMed DOI

Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 33:369–85.10.1053/j.seminoncol.2006.04.003 PubMed DOI

Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials (2013) 34:8690–707.10.1016/j.biomaterials.2013.07.100 PubMed DOI

Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 87:4207–11.10.1073/pnas.87.11.4207 PubMed DOI PMC

Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 89:2965–9.10.1073/pnas.89.7.2965 PubMed DOI PMC

Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci (2009) 16:748–54.10.1016/j.jocn.2008.12.005 PubMed DOI

Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 55:3140–8. PubMed

Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J (2013) 280:5350–70.10.1111/febs.12393 PubMed DOI

Hernandez-Pedro NY, Rangel-Lopez E, Vargas Felix G, Pineda B, Sotelo J. An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis (2013) 2013:716813.10.1155/2013/716813 PubMed DOI PMC

Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol (2015) 5:5.10.3389/fonc.2015.00005 PubMed DOI PMC

Thorne AH, Zanca C, Furnari F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol (2016) 18:914–8.10.1093/neuonc/nov319 PubMed DOI PMC

Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs (2015) 33:671–8.10.1007/s10637-015-0234-6 PubMed DOI

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, et al. AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma. Mol Cancer Ther (2015) 14:1614–24.10.1158/1535-7163.MCT-14-1078 PubMed DOI

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol (2015) 17:854–61.10.1093/neuonc/nou348 PubMed DOI PMC

Choi BD, Archer GE, Mitchell DA, Heimberger AB, Mclendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 19:713–23.10.1111/j.1750-3639.2009.00318.x PubMed DOI PMC

Malkki H. Trial watch: glioblastoma vaccine therapy disappointment in phase III trial. Nat Rev Neurol (2016) 12:190.10.1038/nrneurol.2016.38 PubMed DOI

Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs (2016) 8:659–71.10.1080/19420862.2016.1156829 PubMed DOI PMC

Ruella M, Levine BL. Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. Ann Transl Med (2016) 4:13.10.3978/j.issn.2305-5839.2015.10.11 PubMed DOI PMC

Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, et al. Are BiTEs the “missing link” in cancer therapy? Oncoimmunology (2015) 4:e1008339.10.1080/2162402X.2015.1008339 PubMed DOI PMC

McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol (2012) 8:687–95.10.2217/fon.12.54 PubMed DOI

List T, Neri D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs (2012) 4:775–83.10.4161/mabs.22271 PubMed DOI PMC

Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs (2015) 7:584–604.10.1080/19420862.2015.1029216 PubMed DOI PMC

Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood (2015) 125:4024–31.10.1182/blood-2014-12-614636 PubMed DOI PMC

Reusch U, Harrington K, Gudgeon C, Fucek I, Ellwanger K, Weichel M, et al. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res (2016) 22:5829–38.10.1158/1078-0432.CCR-16-0350 PubMed DOI

Kipriyanov SM, Kupriyanova OA, Little M, Moldenhauer G. Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. J Immunol Methods (1996) 196:51–62.10.1016/0022-1759(96)00115-9 PubMed DOI

Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J (2004) 18:1704–6.10.1096/fj.04-1513fje PubMed DOI

Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng (1997) 10:445–53.10.1093/protein/10.4.445 PubMed DOI

Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer (2000) 88:962–9.10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U PubMed DOI

Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2013) 110:270–5.10.1073/pnas.1219817110 PubMed DOI PMC

Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer (2005) 92:1069–77.10.1038/sj.bjc.6602470 PubMed DOI PMC

Little M, Welschof M, Braunagel M, Hermes I, Christ C, Keller A, et al. Generation of a large complex antibody library from multiple donors. J Immunol Methods (1999) 231:3–9.10.1016/S0022-1759(99)00164-7 PubMed DOI

Little M. Recombinant Antibodies for Immunotherapy. New York, NY: Cambridge University Press; (2009).

Marks JD, Hoogenboom HR, Bonnert TP, Mccafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol (1991) 222:581–97.10.1016/0022-2836(91)90498-U PubMed DOI

Zhai W, Glanville J, Fuhrmann M, Mei L, Ni I, Sundar PD, et al. Synthetic antibodies designed on natural sequence landscapes. J Mol Biol (2011) 412:55–71.10.1016/j.jmb.2011.07.018 PubMed DOI

Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von Der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol (1999) 293:41–56.10.1006/jmbi.1999.3156 PubMed DOI

Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods (2004) 287:147–58.10.1016/j.jim.2004.01.024 PubMed DOI

Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 6:375–86.10.1586/17512433.2013.811806 PubMed DOI PMC

Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 279:30375–84.10.1074/jbc.M401218200 PubMed DOI

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther (2015) 14:1141–51.10.1158/1535-7163.MCT-14-0820 PubMed DOI

Okamoto S, Yoshikawa K, Obata Y, Shibuya M, Aoki S, Yoshida J, et al. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer (1996) 73:1366–72.10.1038/bjc.1996.260 PubMed DOI PMC

Wikstrand CJ, Mclendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res (1997) 57:4130–40. PubMed

Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol (1998) 4:148–58.10.3109/13550289809114515 PubMed DOI

Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res (1995) 1:859–64. PubMed

Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A (1996) 93:14815–20.10.1073/pnas.93.25.14815 PubMed DOI PMC

Kuan CT, Wikstrand CJ, Bigner D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 8:83–96.10.1677/erc.0.0080083 PubMed DOI

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res (2001) 61:5355–61. PubMed

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 104:4071–6.10.1073/pnas.0611693104 PubMed DOI PMC

Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem (2011) 286:5913–20.10.1074/jbc.M110.192252 PubMed DOI PMC

Archer GE, Sampson JH, Lorimer IA, Mclendon RE, Kuan CT, Friedman AH, et al. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res (1999) 5:2646–52. PubMed

Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res (2000) 6:2835–43. PubMed

Hills D, Rowlinson-Busza G, Gullick WJ. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer (1995) 63:537–43.10.1002/ijc.2910630414 PubMed DOI

Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res (1995) 55:4375–82. PubMed

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther (2016) 15:661–9.10.1158/1535-7163.MCT-15-0901 PubMed DOI

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res (2007) 13:1911–25.10.1158/1078-0432.CCR-06-1453 PubMed DOI

Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A (2010) 107:12605–10.10.1073/pnas.1000976107 PubMed DOI PMC

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 23:1043–53.10.1089/hum.2012.041 PubMed DOI PMC

Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One (2014) 9:e94281.10.1371/journal.pone.0094281 PubMed DOI PMC

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, Mcgettigan SE, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med (2015) 7:275ra222.10.1126/scitranslmed.aaa4963 PubMed DOI PMC

Safdari Y, Farajnia S, Asgharzadeh M, Omidfar K, Khalili M. humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII. Int Immunopharmacol (2014) 18:304–10.10.1016/j.intimp.2013.12.006 PubMed DOI

Klausz K, Berger S, Lammerts Van Bueren JJ, Derer S, Lohse S, Dechant M, et al. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci (2011) 102:1761–8.10.1111/j.1349-7006.2011.02019.x PubMed DOI

Landry RC, Klimowicz AC, Lavictoire SJ, Borisova S, Kottachchi DT, Lorimer IA, et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. J Mol Biol (2001) 308:883–93.10.1006/jmbi.2001.4628 PubMed DOI

Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, et al. Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol (2010) 10:72.10.1186/1472-6750-10-72 PubMed DOI PMC

Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol (2011) 29:2493–8.10.1200/JCO.2010.32.7270 PubMed DOI

Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today (2015) 20:838–47.10.1016/j.drudis.2015.02.008 PubMed DOI

Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol (2015) 67:95–106.10.1016/j.molimm.2015.01.003 PubMed DOI

Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther (2013) 21:895–903.10.1038/mt.2013.14 PubMed DOI PMC

Xu W, Bi Y, Kong J, Zhang J, Wang B, Li K, et al. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo. Oncotarget (2016) 7:24752–65.10.18632/oncotarget.8407 PubMed DOI PMC

Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, et al. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res (2006) 12:3792–802.10.1158/1078-0432.CCR-06-0141 PubMed DOI

Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 39:29–36.10.1002/gcc.10300 PubMed DOI

Stockhausen MT, Broholm H, Villingshoj M, Kirchhoff M, Gerdes T, Kristoffersen K, et al. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res (2011) 317:1513–26.10.1016/j.yexcr.2011.04.001 PubMed DOI

Engaging T cells for cleanup